Welcome to our dedicated page for Ventyx Biosciences SEC filings (Ticker: VTYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, cash runway disclosures, and milestone payments are buried deep in Ventyx Biosciences’ SEC documents. Finding the next hint on its TYK2 inhibitor or NLRP3 program can take hours—and missing an 8-K update could cost you. That’s why investors searching for “Ventyx Biosciences SEC filings explained simply” start here.
Stock Titan extracts the details that matter. Our AI reads every VTYX 10-K and 10-Q the moment they hit EDGAR, then highlights R&D spend, pipeline progress, and liquidity metrics. Want “Ventyx Biosciences quarterly earnings report 10-Q filing” without wading through footnotes? Need “Ventyx Biosciences 8-K material events explained” after a trial readout? We surface it in plain English, alongside real-time alerts for “Ventyx Biosciences Form 4 insider transactions.”
- Track “Ventyx Biosciences insider trading Form 4 transactions” and receive notifications the instant executives buy or sell.
- Compare R&D trends across periods with our “Ventyx Biosciences earnings report filing analysis.”
- Review governance details in the “Ventyx Biosciences proxy statement executive compensation” section, simplified by AI.
Whether you’re monitoring cash burn before the next Phase II readout or checking “Ventyx Biosciences annual report 10-K simplified” for risk factors, our platform keeps you ahead. From “understanding Ventyx Biosciences SEC documents with AI” to spotting “Ventyx Biosciences executive stock transactions Form 4,” every disclosure is translated into actionable insight—updated in real time and ready when you are.
Ventyx Biosciences, Inc. (VTYX) filed a Form 4 reporting an open market-equivalent share purchase by its Chief Medical Officer. The reporting person acquired 3,000 shares of Ventyx common stock on November 17, 2025 through the company’s 2021 Employee Stock Purchase Plan. The shares were bought at a price of $1.03 per share, calculated as 85% of the closing price on May 15, 2025, in line with the ESPP terms.
Following this transaction, the reporting person beneficially owns 6,000 shares of Ventyx common stock, held directly. The filing notes that the transaction is exempt under Rule 16b-3(c) and that it was reported on a voluntary basis in connection with the ESPP purchase period running from May 15, 2025 through November 14, 2025.
Ventyx Biosciences, Inc. (VTYX)November 17, 2025, the officer acquired 1,767 shares of common stock at a purchase price of $1.03 per share through the company’s 2021 Employee Stock Purchase Plan (ESPP). After this transaction, the officer beneficially owns 5,313 shares of Ventyx common stock in direct ownership.
The filing notes that the purchase relates to the ESPP purchase period running from May 15, 2025 through November 14, 2025 and that the transaction is exempt under Rule 16b-3(c). The shares were bought at 85% of the closing price on May 15, 2025, consistent with the terms of the 2021 ESPP.
Ventyx Biosciences (VTYX) reported Q3 2025 results. The company recorded a net loss of $22.8 million for the quarter and $77.3 million year-to-date. Operating expenses declined to $24.9 million from $38.6 million a year ago, driven by lower research and development spend ($17.7 million vs. $30.6 million) while general and administrative expenses were $7.2 million (vs. $7.9 million). Interest income contributed $2.1 million in the quarter.
Liquidity remained solid with $31.97 million in cash and cash equivalents and $160.67 million in marketable securities as of September 30, 2025. Total assets were $211.5 million and stockholders’ equity was $191.4 million. Shares outstanding were 71,336,958 as of September 30, 2025; 71,358,638 were outstanding as of November 3, 2025. The pipeline update highlights ongoing Phase 2 work for NLRP3 inhibitors (VTX2735 in recurrent pericarditis; VTX3232 in Parkinson’s disease and cardiometabolic risk) and partnering plans for tamuzimod in ulcerative colitis.
Ventyx Biosciences (VTYX)
Ventyx Biosciences (VTYX) announced top-line data from its Phase 2 trial of VTX3232, a CNS-penetrant NLRP3 inhibitor, in participants with obesity and cardiovascular risk factors. The company will host a conference call at 4:30pm ET on October 22, 2025 to review the results.
The press release and a topline results presentation are provided as Exhibits 99.1 and 99.2. The information was furnished under Regulation FD and is not deemed filed under Section 18 of the Exchange Act.
Point72 (Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen) reports beneficial ownership of 5,895,069 shares of Ventyx Biosciences common stock, representing 8.3% of the class as of the close of business on June 30, 2025. The filing clarifies that Point72 Asset Management has shared voting and dispositive power over these Shares held by Point72 Associates, that Point72 Capital Advisors is the general partner, and that Mr. Cohen controls both entities. The statement notes the shares were not acquired to change control of the issuer and that Cubist Systematic Strategies, LLC acts as a sub-advisor for a portion of the reported position.
FAQ
What is the current stock price of Ventyx Biosciences (VTYX)?
What is the market cap of Ventyx Biosciences (VTYX)?
